← Oncology Approval Tracker

FDA DECISION ·

Tecentriq / Tecentriq Hybreza

atezolizumab or atezolizumab and hyaluronidase-tqjs · Genentech

FDA approvalNew or expanded indicationBladder cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adjuvant monotherapy for adults with muscle-invasive bladder cancer after cystectomy and circulating tumor DNA molecular residual disease (ctDNA MRD) detected by an FDA-authorized test.

LAMPGEN ANALYSIS

Why it matters

This approval makes a post-surgery molecular signal actionable in bladder cancer. The randomized IMvigor011 population came from serial testing after cystectomy.

What research teams should watch

Define who orders and tracks serial MRD tests, who receives positive results and how referrals are closed. The operational question is whether patients can complete testing and start therapy in time.

Clinical operations takeaway

Assign an owner to each handoff from the scheduled draw and lab receipt to the returned result and documented follow-up. Review missed draws, late reports, and unresolved actions during site and study reviews.

Plan biomarker screening and specimen workflows

Related study operations checklist

See the staffing responsibilities, timing, and handoff questions for this study setting.

Perioperative muscle-invasive bladder cancer

PRIMARY RECORDS

Sources